Scarica l'app Stockscreener
8.57
2.15%
0.18
Dopo l'orario di chiusura:
8.58
0.010
+0.12%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Optimizerx Corp Borsa (OPRX) Ultime notizie
OptimizeRx stock gets a higher USD 11.00 price target - AD HOC NEWS
OPTIMIZERx Corp (NASDAQ: OPRX) Share Price, OPRX Stock News, OPRX Share Price & Updates - kalkine.ca
Squarepoint Ops LLC Sells 132,507 Shares of OptimizeRx Corp. $OPRX - MarketBeat
OptimizeRx Expands Authenticated HCP Reach on The Trade Desk - MarTech Cube
Will OPRX's OpenPath Deal Help TTD Capture More Healthcare Ad Dollars? - Zacks Investment Research
Will OPRX's OpenPath Deal Help TTD Capture More Healthcare Ad Dollars? - TradingView
OptimizeRx Corporation (OPRX) Stock Price, News, Quote & History - Yahoo! Finance Canada
OptimizeRx Partners With The Trade Desk To Widen Its Healthcare Ad Network - Asianet Newsable
OptimizeRx Corp. And The Trade Desk Bring Net New Authenticated HCP Reach To The Trade Desk Through OpenPath - marketscreener.com
OptimizeRx Brings Net New Authenticated HCP Reach to The Trade Desk Through OpenPath - Stock Titan
OptimizeRx Corp. (NASDAQ:OPRX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
OptimizeRx Expands Natural Language Audience Builder to Unify HCP and DTC Audience Intelligence - The Manila Times
One prompt now builds patient and doctor audiences. OptimizeRx expanded the tool. - Stock Titan
OptimizeRx to Participate in the 10th Annual Lake Street Best Ideas Growth Conference - marketscreener.com
A 10th annual growth conference is set for New York, with OptimizeRx taking part. - Stock Titan
Optimizerx Stock Price Forecast. Should You Buy OPRX? - StockInvest.us
OptimizeRx (OPRX) insider stock withheld for taxes - Stock Titan
OptimizeRx appoints Troy Sarich as company advisor By Investing.com - Investing.com Canada
OptimizeRx appoints Troy Sarich as company advisor - investing.com
OptimizeRx Appoints Former Johnson & Johnson Executive Troy Sarich as Company Advisor - Quiver Quantitative
OptimizeRx Appoints Pharma Commercialization and AI Expert Troy Sarich as Company Advisor - Yahoo Finance UK
OptimizeRx Corp. (NASDAQ:OPRX) Given Average Rating of "Moderate Buy" by Analysts - marketbeat.com
OptimizeRx (NASDAQ: OPRX) COO keeps 25,187 shares after RSU tax withholding - Stock Titan
OptimizeRx (OPRX) records insider share trade - Stock Titan
OPRX | OptimizeRx Corporation Common Stock FinancialsRevenue Breakdown - Quiver Quantitative
OptimizeRx (OPRX) Q2 2026 Earnings Call Transcript - AOL.com
OptimizeRx (OPRX) EPS and Revenue: Profit Per Share Clears Its Benchmark in the Current Update; Closing Move - vinanet.vn
OptimizeRx Corp (OPRX) Stock News Today - TradingKey
symbol__ Stock Quote Price and Forecast - CNN
OptimizeRx (OPRX) Slips to $8.72 as Shares Consolidate Near Range MidpointInverse ETF Flow - vinanet.vn
OptimizeRx Corp (OPRX) gains 6.7% institutional holder in Kennedy Capital - Stock Titan
Conferencia de resultados del segundo trimestre fiscal de 2026 de OptimizeRx (OPRX): Reitera previsiones mientras los ingresos caen un 30% - TradingKey
OptimizeRx (NASDAQ:OPRX) Stock Price Expected to Rise, Citizens Jmp Analyst Says - marketbeat.com
Citizens raises OptimizeRx stock price target on macro stability By Investing.com - Investing.com Nigeria
Citizens raises OptimizeRx stock price target on macro stability - Investing.com
Renaissance Technologies LLC Has $1.36 Million Stock Position in OptimizeRx Corp. $OPRX - MarketBeat
OptimizeRx (OPRX) Earnings Call zu Q2 des Geschäftsjahres 2026: Prognose bestätigt, während der Umsatz um 30 % sinkt - TradingKey
OptimizeRx (OPRX) Fiscal Q2 2026 Earnings Call: Guidance Reaffirmed as Revenue Falls 30% - TradingKey
Stifel cuts OptimizeRx stock price target on revenue headwinds By Investing.com - Investing.com Australia
OptimizeRx Reaffirms 2026 Outlook Amid Revenue Decline - The Globe and Mail
OptimizeRx (OPRX) revenue falls 21% as margins and cash flow hold - Stock Titan
Stifel cuts OptimizeRx stock price target on revenue headwinds - Investing.com
OPTIMIZERx earnings beat by $0.06, revenue topped estimates - Investing.com Nigeria
OptimizeRx Corporation Q2 2026 Earnings Call Summary - Yahoo Finance
OptimizeRx Reports Second Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance - The Manila Times
OptimizeRx Corp (OPRX) (Q2 2026) Earnings Call Highlights: Navigating Revenue Headwinds with ... - Yahoo! Finance Canada
OptimizeRx Announces Finance Leadership Appointments to Support the Next Phase of Growth - Technology Magazine
OptimizeRx Q2 Earnings Call Highlights - MarketBeat
OPRX Looks 45.1% Undervalued on GF Value™ - GuruFocus
OptimizeRx Q2 adj. EPS beats estimate as sales fall 30% YoY - scanx.trade
Earnings call transcript: OptimizeRx beats Q2 2026 profit view as shares slip - Investing.com Australia
OptimizeRx Corp. (OPRX) Q2 Earnings and Revenues Top Estimates - Yahoo Finance
OptimizeRx (NASDAQ:OPRX) Announces Earnings Results, Beats Estimates By $0.05 EPS - MarketBeat
OptimizeRx Latest Results: FY2026 sales guidance affirmed at $95M-$100M - scanx.trade
0.13%
2.13%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):